EAC 2020 Update in Allergy, Asthma and Immunology
The EAC 2020 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning advancements in the diagnosis and treatment strategies for patients. Topics of discussion will include updates in diagnosis and treatment of HAE, biologics for severe asthma, allergic skin diseases, advances in peanut allergy treatments and management of penicillin and other antibiotic allergies.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Allergy Conference. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 15.5 contact hours.
Commercial Support
This activity is supported in part by independent medical education grants from CSL Behring, Stallergenes Greer and Optinose.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity the participant should be able to:
- Prescribe optimal therapy in patients with food allergy
- Diagnose and manage peanut allergy
- Diagnose and manage eosinophilic esophagitis
- Diagnose and manage drug allergy
- Diagnose and manage hereditary angioedema
- Discuss current and future allergy immunotherapy treatment options for respiratory allergies
- Outline to the use of biologics for allergic diseases, including asthma, chronic urticaria and nasal polyps
- Evaluate for potential immunodeficiency
- Diagnose and manage patietns with mast cell activiation syndrome
EAC 2020 Update in Allergy, Asthma and Immunology
The Breakers – Palm Beach, Florida
August 16 – 18, 2020
Sunday, August 16, 2020
1:00 – 1:30 When to consider Immunologic evaluation in patients presenting with “rash”, Jennifer Leiding, MD
1:30 – 2:00 CRScNP Management in the era of biologics, Michael Blaiss, MD
2:00 – 2:15 Q & A
2:15 – 2:45 Combination ics/beta-agonist inhaler as reliever therapy: FDA vs new guidelines, Leonard Bacharier, MD
2:45 – 3:15 Chronic urticaria: Best practice for evaluation and treatment, Jonathan Bernstein, MD
3:15 – 3:30 Q & A
4:30 – 5:05 Assessing the unmet need for current and future biologics in pediatric asthma management, Leonard Bacharier, MD
5:05 – 5:40 Safety of SLIT vs. SCIT: An update on adverse events and fatalities, Russell Settipane, MD
5:40 – 6:15 Efficacy of SLIT tablets in pollen and dust mite allergy, Lawrence DuBuske, MD
6:15 – 6:30 Q & A
Monday, August 17, 2020
7:45 – 8:35 Pro: Anti-IL5 therapies are biologics of choice for severe eosinophilic asthma, Mario Castro, MD
Con: Anti-IL5 therapies are NOT biologics of choice for severe eosinophilic asthma, Rey Panettieri, MD
8:35 – 8:45 Q & A
8:45 – 10:00 PBL - A 36-year old women with repeated episodes of hives, hypotension and diarrhea.
10:00 – 10:45 Coffee Break/Visit Exhibits/Posters
10:45 – 11:00 Post PBL Case Summary, Jonathan Bernstein, MD
11:00 – 11:30 MCAS: Myths and realities, Jonathan Bernstein, MD
11:30 – 11:35 Q & A
11:35 – 12:05 Weighing the benefits and risks of peanut OIT in clinical practice, Aikaterini Anagnostou, MD
12:05 – 12:15 Q & A
1:15 – 1:45 Immunodeficiency update, Jennifer Leiding, MD
1:45 – 2:15 When to consider patch testing in atopic dermatitis, Marcella Aquino, MD
2:15 – 2:45 The Allergist’s role in the COVID-19 pandemic, Joseph Bellanti, MD
2:45 – 3:00 Q & A
Tuesday, August 18, 2020
7:45 – 8:10 Telemedicine: How has it changed clinical allergy practice, and what will the post - COVID future look like?, Justin Greiwe, MD
8:10 – 8:35 Opportunities and challenges of shared-decision making in the telemedicine era, Don Bukstein, MD
8:35 – 8:45 Q & A
8:45 – 10:00 PBL - An 18 -year old male with dysphagia
10:00 – 10:45 Coffee Break/Visit Exhibits/Posters
10:45 – 11:00 Post PBL Case Summary, Karen Hsu Blatman, MD
11:00 – 11:30 The role of the allergist in the multidisciplinary evaluation and management of EoE, Karen Hsu Blatman, MD
11:30 – 11:35 Q & A
11:35 – 12:05 Immediate hypersensitivity testing for drug allergies, Aleena Banerji, MD
12:05 – 12:15 Q & A
1:15 – 1:45 HAE: Guideline-based care and beyond, Aleena Banerji, MD
1:45 – 2:15 Best Practice for oral food challenges – Which patients need a challenge and when?, Justin Greiwe, MD
2:15 – 2:45 Peanut Diagnostics: A GRADE Guideline, Dana Wallace, MD
2:45 – 3:00 Q & A
3:00 Meeting adjourn
All identified conflicts of interest have been resolved.
Aikaterini Anagnostou, MD – Speaker
Disclosures: Independent Contractor/contracted research: Aimmune
Leonard Bacharier, MD – Speaker
Disclosures: Consultant/consulting fee: AstraZeneca, DBV Technologies, GlaxoSmithKline, Sanofi, Regeneron; Speaker/honoraria: AstraZeneca GlaxoSmithKline, Sanofi, Regeneron, Novartis;
Aleena Banerji, MD – Speaker
Disclosures: Advisory Board/honorarium: Shire, CSL Behring, Biocryst, Pharming, Pharvaris, Kalvista; Research Grant/honorarium: Biocryst, Shire
Jonathan Bernstein, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, AstraZeneca, Biocryst, CSL Behring, Dyax, Genentech, Novartis, Merck, Regeneron, Sanofi, Shire; Speaker/honoraria: ALK, AstraZeneca, CSL Behring, Dyax, Genentech, Novartis, Regeneron, Sanofi, Shire; Independent Contractor/contracted research: ALK, AstraZeneca, Biocryst, Boehringer Ingelheim, CSL Behring, Dyax, Genentech, Novartis, Merck, Regeneron, Sanofi, Shire, Stallergenes, Teva; Advisory Board/honorarium: ALK, AstraZeneca, Biocryst, CSL Behring, Dyax, Genentech, Novartis, Regeneron, Shire
Michael Blaiss, MD – Speaker
Disclosures: Consultant/consulting fee: Pfizer, Merck, Hycor, ALK, Greer, Sanofi, JDP Therapeutics, PMD Healthcare, DBV Technologies
Karen Hsu Blatman, MD – Speaker
Disclosures: Independent Contractor/contracted research: Takeda
Don Bukstein, MD – Speaker
Disclosures: Speaker/honorarium: AstraZeneca, Aventis, Teva, Sanofi, Regeneron, Genentech, Circassia; Independent Contractor/contracted research – Circassia
Mario Castro, MD – Speaker
Disclosures: Consultant/consulting fee: Novartis, Sanofi, Teva, Genentech; Speaker/honorarium: AstraZeneca, GlaxoSmithKline, Sanofi, Teva, Genentech, Regeneron; Research Study/consulting fee: AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Pulmatrix, Shionogi
William Corrao, MD – Planner
Disclosures: Speaker/honorarium: GlaxoSmithKline, Boehringer Ingelheim
Ray Davis, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, Baxalta, Shire, Genentech, Novartis, Circassia, Takeda, DBV Technologies, Maculogix; Speaker/honorarium: DBV Technologies, Novartis
Lawrence DuBuske, MD – Speaker
Disclosures: Consultant/consulting fee: ALK, AstraZeneca, Regeneron, Sanofi, Allergy Therapeutics, Abionic; Speaker/honorarium: ALK, AstraZeneca, Novartis, Regeneron, Sanofi; Advisory Board/honorarium: ALK, AstraZeneca, Regeneron, Sanofi
Justin Greiwe, MD – Speaker
Disclosures: Speaker/honorarium: AstraZeneca, Regeneron, Sanofi; Advisory Board/consulting fee: AstraZeneca
Jennifer Leiding, MD – Speaker
Disclosures: Consultant/consulting fee: CSL Behring, Horizon Therapeutics; Speaker/honorarium: CSL Behring, Horizon Therapeutics
Advisory Board/consulting fee: CSL Behring, Horizon Therapeutics, Orchard Therapeutics
Rey Panettieri, Jr., MD – Speaker
Disclosures: Consultant – Novartis, DBV Technologies; Speaker/honorarium: AstraZeneca, Genentech, Sanofi; Advisory Board//consulting fee: AstraZeneca, Medimmune, Research Institute for Fragrance Materials, Equillium, Theravance, Avillion; Independent Contractor/consulting fee: AstraZeneca, Medimmune, Research Institute for Fragrance Materials, Equillium, Genentech, Oncoarendi, Metera
Robert Settipane, MD – Planner
Disclosures: Independent Contractor/contracted research: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Teva, Novartis, Syneos Health, Biocryst, Avillion
Russell Settipane, MD – Planner/Speaker
Disclosures: Speaker/honorarium: ALK, Genentech, Regeneron, Teva, Pharming, Shire, Sunovion, Boehringer Ingelheim; Consultant/consulting fees: Boehringer Ingelheim, RB Health; Advisory Board/contracted research: ALK, AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, Teva, Pharming; Independent Contractor/honorarium: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Teva, Syneos Health, Novartis, Biocryst, Avillion
Dana Wallace, MD – Speaker
Disclosures: Consultant/consulting fee: Mylan, Kaleo, Bryan; Speaker/honorarium: Optinose, ALK, Sanofi
The following have nothing to disclose:
Marcella Aquino, MD – Speaker
Joseph Bellanti, MD – Planner/Speaker
William Greisner, III, MD – Planner/Moderator/Reviewer
Katelyn Loiselle, RN – Planner
Ginny Loiselle – Coordinator
Michael Slaughter, MD – Planner/Moderator/Reviewer
Kelli Wilson - Planner
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 15.50 AMA PRA Category 1 Credit™
- 15.50 Attendance
- 15.50 CBRN